Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2012

View Archived Issues

Liposomal irinotecan shows benefit in metastatic colorectal cancer

Risk loci for multiple myeloma identified

Phase IIa trial assesses daclatasvir/asunaprevir in difficult-to-treat hepatitis C

BioLineRx signs license agreement with Genoscience

Cephalon scientists disclose synthesis, pharmacological and first clinical data on CEP-11981

Novel polypeptides prepared by Zealand Pharma

Novel phosphodiesterase 10A inhibitors synthesized in Japan

New phosphodiesterase 4 inhibitors presented by Leo Pharma

Abbott profiles pipeline progress of 2011

German team patents new agents with neurogenic and neurotrophic properties

Recruitment begins in phase Ib/II U3-1287 combination study

Vertex Pharmaceuticals patents new serine/threonine-protein kinase ATR inhibitors

Merck & Co. designs new protein kinase inhibitors

RPCI launches first-ever trial of dendritic vaccine plus rapamycin

Celgene announces merger agreement

EMA grants orphan drug status to Celator product

Biogen Idec and Elan evaluate Tysabri in secondary progressive MS

Auxilium Pharmaceuticals doses first patients in Xiaflex study

Studies detail beta-amyloid detection with florbetapir F 18 PET

Kancera subsidiary and Agios Pharmaceuticals launch alliance

Lpath suspends dosing in clinical studies of iSONEP

BioAlliance Pharma outlines major achievements of 2011 and prospects for 2012

Enrollment begins in Japan in phase III trials of orteronel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...